局部晚期甲状腺癌新辅助治疗的现状与展望  

Current status and perspectives of neoadjuvant therapy for locally advanced thyroid cancer

作　　者：张宇 王宇 ZHANG Yu;WANG Yu(Department of Head and Neck Surgery,Fudan University Shanghai Cancer Center,Shanghai 200000,P.R.China)

机构地区：[1]复旦大学附属肿瘤医院头颈外科,上海200000

出　　处：《中国普外基础与临床杂志》2024年第11期1295-1299,共5页Chinese Journal of Bases and Clinics In General Surgery

基　　金：国家自然科学基金面上项目(项目编号:82072951);上海市科委重点领域创新计划项目(项目编号:22Y21900100);上海市抗癌协会项目(项目编号:SACA-AX202213)。

摘　　要：初诊时,局部晚期甲状腺癌患者往往难以进行根治性手术,这成为目前甲状腺癌治疗的一大挑战。随着甲状腺癌系统治疗的不断发展,多项研究表明,全身新辅助治疗能够使部分患者的肿瘤缩小,从而增加获得完整切除的机会,并改善患者的预后。靶向治疗作为新辅助治疗的核心组成部分,发挥着重要作用。与此同时,免疫治疗的潜在疗效也逐渐受到关注,展现出良好的前景。笔者对局部晚期甲状腺癌新辅助治疗的研究进展及存在的问题进行了总结,并期待更多高质量的临床研究为局部晚期甲状腺癌的新辅助治疗提供更为坚实的循证依据,以拓展治疗选择的广度。Patients with locally advanced thyroid cancer often face challenges in achieving radical surgery during initial diagnosis.This has become a significant hurdle in the treatment of thyroid cancer.With the continuous development of systemic therapy for thyroid cancer,several studies have demonstrated that neoadjuvant therapy can shrink tumors in some patients,thereby increasing the chances of complete resection and improving prognosis.Targeted therapy plays a crucial role as a core component of neoadjuvant treatment.Simultaneously,the potential efficacy of immunotherapy has gained attention,showing promising prospects.We aim to summarize the research progress and existing issues regarding neoadjuvant therapy for locally advanced thyroid cancer.We look forward to more high-quality clinical studies providing robust evidence for neoadjuvant therapy in locally advanced thyroid cancer,expanding the breadth of treatment options.

关 键 词：局部晚期甲状腺癌 新辅助治疗 根治性切除 酪氨酸激酶抑制剂 免疫治疗 

分 类 号：R736.1[医药卫生—肿瘤]